HCPCS
Q2050
10 mg = 1 unit
Phase 1
Identify what you're billing
Liposomal doxorubicin (Q2050) is NOT conventional doxorubicin (J9000). Confirm before billing.
Doxorubicin formulation comparison — Doxil/Lipodox (Q2050) vs conventional (J9000) FDA verified May 2026
Same active molecule, very different drug. Different code, different label, different toxicity, different price.
Doxorubicin is delivered in two distinct FDA-approved IV products. Pegylated liposomal doxorubicin (Doxil, originator Janssen; Lipodox and other generics) encapsulates the drug in long-circulating PEG-coated liposomes. Conventional doxorubicin HCl is the free-drug form. They are not interchangeable and substituting one for the other is both a clinical error and a billing error.
| Doxil / Lipodox (liposomal) | Conventional doxorubicin | |
|---|---|---|
| HCPCS | Q2050 ("Doxorubicin inj 10 mg" liposomal NOS) | J9000 ("Inj doxorubicin HCl 10 mg") |
| Unit size | 10 mg = 1 unit | 10 mg = 1 unit |
| Q2 2026 ASP+6% | $71.861 per 10 mg unit | $2.729 per 10 mg unit |
| Cost ratio | Liposomal is approximately 26× more expensive per mg of doxorubicin. | |
| Formulation | Pegylated liposome encapsulation (PEG-coated long-circulating) | Free drug in solution |
| Pharmacokinetics | Long half-life (~55 hr); preferential tumor uptake; reduced cardiac peak exposure | Short half-life; broad biodistribution |
| FDA label indications | Ovarian (post-platinum), AIDS-KS, MM + bortezomib | Many: AML, ALL, Wilms, neuroblastoma, sarcomas, breast, ovarian, gastric, transitional cell bladder, thyroid, lymphomas, etc. |
| Lifetime cumulative cap | 550 mg/m² (liposomal pharmacokinetics) | 450–550 mg/m² (institutional protocols vary) |
| Cardiotoxicity | Real risk — cumulative-dose driven, monitor LVEF; reduced acute cardiac peak vs conventional | Classic anthracycline cardiotoxicity (acute + chronic) |
| Hand-foot syndrome | ~50% incidence — hallmark Doxil toxicity | <5% incidence |
| Alopecia | Less common | Common (universal at curative doses) |
| Vesicant? | Less severe extravasation than conventional, but irritant; treat as vesicant per institutional policy | Yes — classic anthracycline vesicant |
| Infusion time | ~60 minutes (start 1 mg/min for first dose) | IV push or short infusion |
| Premedication | Generally not required, but slow first-dose titration mandatory | Antiemetic prophylaxis per regimen |
Substitution is a billing error. Liposomal and conventional doxorubicin are different
drugs with different codes, different ASPs, different labels, and different toxicity profiles. A claim
that bills Q2050 when J9000 was administered (or vice versa) will be denied. The PA, the chart, the
admin record, and the claim must all match the formulation actually given.
Cross-reference: See Doxorubicin (J9000) reference page
for the conventional anthracycline.
Dosing & unit math FDA label May 2026
Indication-specific dosing matrix. Q2050 is a 10 mg unit, so doses round to whole units; BSA-based dosing produces frequent partial-vial waste.
| Indication | Dose | Schedule | Sample 1.7 m² patient |
|---|---|---|---|
| Ovarian (post-platinum failure) | 50 mg/m² | q4wk IV | 85 mg = 9 units (round up; track waste) |
| AIDS-related Kaposi sarcoma | 20 mg/m² | q3wk IV | 34 mg = 4 units (round up; track waste) |
| Multiple myeloma + bortezomib | 30 mg/m² | Day 4 of each 21-day cycle (after bortezomib Days 1, 4, 8, 11) | 51 mg = 6 units (round up; track waste) |
First-dose infusion rate — mandatory slow start
For the first infusion, start at 1 mg/min to monitor for infusion reactions (back pain, flushing, chest tightness, dyspnea, hypotension). If no reaction in the first 10–15 minutes, titrate up to complete the dose over approximately 60 minutes. Subsequent infusions can be given over 60 minutes if the first was tolerated.
Worked example — 1.7 m² ovarian patient, 50 mg/m² q4wk
# Calculate dose
BSA: 1.7 m²
Prescribed: 50 mg/m²
Actual dose: 1.7 × 50 = 85 mg
# Vial selection
Available: 20 mg vials and 50 mg vials
Best fit for 85 mg: two 50 mg vials = 100 mg total (no 80 mg combo possible)
Drug administered: 85 mg
Drug discarded: 15 mg
# Bill in Q2050 units (10 mg per unit)
Administered: 85 mg / 10 = 8.5 → round per MAC policy (typically 9 units)
Wasted: 15 mg / 10 = 1.5 → round per MAC policy (typically 2 units)
Total billed: 9 units JZ + 2 units JW
# Q2 2026 reimbursement
9 units × $71.861 = $646.75 (administered) + 2 units × $71.861 = $143.72 (waste)
Total drug payment: ~$790.47 per cycle before sequestration
BSA: 1.7 m²
Prescribed: 50 mg/m²
Actual dose: 1.7 × 50 = 85 mg
# Vial selection
Available: 20 mg vials and 50 mg vials
Best fit for 85 mg: two 50 mg vials = 100 mg total (no 80 mg combo possible)
Drug administered: 85 mg
Drug discarded: 15 mg
# Bill in Q2050 units (10 mg per unit)
Administered: 85 mg / 10 = 8.5 → round per MAC policy (typically 9 units)
Wasted: 15 mg / 10 = 1.5 → round per MAC policy (typically 2 units)
Total billed: 9 units JZ + 2 units JW
# Q2 2026 reimbursement
9 units × $71.861 = $646.75 (administered) + 2 units × $71.861 = $143.72 (waste)
Total drug payment: ~$790.47 per cycle before sequestration
Rounding policy varies by MAC. Some MACs require rounding up to next whole unit on the
admin line and reporting fractional waste; others permit partial-unit billing. Verify your MAC's
single-dose container rounding policy before submitting Q2050 claims.
Multiple myeloma combo sequencing
For the MM regimen, bortezomib is given on Days 1, 4, 8, and 11 of each 21-day cycle. Doxil is added on Day 4 only, after bortezomib. Bill the chemo admin codes per CPT hierarchy when both are given same-day (96413 for the initial / longest infusion, 96417 for each additional sequential infusion).
NDC reference FDA NDC Directory verified May 2026
| Product | NDC (representative) | Package |
|---|---|---|
| Doxil (Janssen) 20 mg / 10 mL | 59676-960-01 / 59676-0960-01 |
Single-dose vial — 1 per carton |
| Doxil (Janssen) 50 mg / 25 mL | 59676-961-01 / 59676-0961-01 |
Single-dose vial — 1 per carton |
| Lipodox (Sun Pharma generic) 20 mg / 10 mL | Verify current labeler NDC | Single-dose vial |
| Lipodox (Sun Pharma generic) 50 mg / 25 mL | Verify current labeler NDC | Single-dose vial |
Verify the NDC on the actual carton. Multiple generic manufacturers produce pegylated
liposomal doxorubicin under different labeler codes. Capture the 11-digit NDC from the carton dispensed
for each patient and submit it on the claim. Q2050 is a "not otherwise specified" code that accepts
any FDA-approved liposomal doxorubicin NDC.
Phase 2
Code the claim
Cytotoxic chemo admin codes (96413 family) with JZ + JW for waste tracking.
Administration codes CPT verified May 2026
| Code | Description | When to use |
|---|---|---|
96413 |
Chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug | Primary code for Doxil. 60-min infusion fits within the 1-hour window. |
96415 |
Chemotherapy administration, IV infusion; each additional hour | Use when first-dose slow titration extends chair time beyond 1 hour, or for combo regimens that exceed 1 hour total. |
96417 |
Chemotherapy admin, IV infusion; each additional sequential infusion (different drug/substance), up to 1 hour | For MM regimen day-4 sequencing when Doxil is added after bortezomib on the same day. |
96365 / 96366 |
Therapeutic IV infusion (non-chemo) | NOT appropriate. Doxil is a cytotoxic chemotherapy and bills under chemo admin codes. |
Modifiers CMS verified May 2026
JZ + JW — both apply, frequently together
Effective July 1, 2023, CMS requires JZ on every single-dose container claim with no waste, and JW for the discarded portion when waste exists. Doxil's BSA-based dosing with fixed 20 mg and 50 mg vials almost never lands on whole-vial multiples, so partial-vial waste is the norm — bill JZ on the administered units and JW on the wasted units. One of JZ or JW must appear on every Q2050 claim.
Worked modifier example
- Patient 1.6 m², ovarian, 50 mg/m² → 80 mg dose
- Vials used: two 50 mg vials = 100 mg total drawn
- Administered: 80 mg = 8 units → bill 8 units of Q2050 with
JZ - Discarded: 20 mg = 2 units → bill 2 units of Q2050 with
JWon a separate claim line
Do not omit the JW line. CMS audits often catch missing JW on BSA-based oncology claims.
Wasted drug is reimbursable but must be documented.
Modifier 25 — same-day E/M
Use modifier 25 on the E/M code when a significant, separately identifiable evaluation is performed on the same day as the infusion. Routine pre-cycle clinical assessment is bundled.
340B modifiers (JG, TB)
For 340B-acquired Doxil/Lipodox, follow your MAC's current 340B modifier policy.
ICD-10-CM by indication FY2026 verified May 2026
| Indication | ICD-10 family | Notes |
|---|---|---|
| Ovarian cancer (post-platinum failure) | C56.x | C56.1 right, C56.2 left, C56.9 unspecified; document prior platinum failure |
| AIDS-related Kaposi sarcoma | C46.x | C46.0 skin, C46.1 soft tissue, C46.2 palate, C46.3 lymph nodes, C46.5 lung, C46.7 other, C46.9 unspecified; pair with B20 |
| Multiple myeloma (combo with bortezomib) | C90.00 / C90.01 / C90.02 | C90.00 not having achieved remission, C90.01 in remission, C90.02 in relapse; document prior therapy |
Document line of therapy in the chart. All three Doxil indications require failure of
prior therapy in the FDA label (post-platinum for ovarian, post-prior failure for AIDS-KS, post-≥1
prior therapy for MM). PA submissions must include the prior-therapy history.
Site of care & place of service Verified May 2026
Most major commercial payers run aggressive site-of-care utilization management for IV oncology infusibles. UnitedHealthcare and Aetna steer toward physician office, ambulatory infusion suite, or oncology ASC and away from hospital outpatient (HOPD) after the first 1–3 cycles unless toxicity management requires HOPD-level support.
| Setting | POS | Claim form | Payer steering |
|---|---|---|---|
| Physician oncology office | 11 | CMS-1500 / 837P | Preferred by commercial UM |
| Ambulatory infusion suite (AIC) | 49 | CMS-1500 / 837P | Preferred by commercial UM |
| Oncology ASC | 24 | CMS-1500 / 837P | Acceptable |
| Hospital outpatient (on-campus) | 22 | UB-04 / 837I | Disfavored after first 1–3 cycles |
| Hospital outpatient (off-campus PBD) | 19 | UB-04 / 837I | Disfavored after first 1–3 cycles |
| Patient home | 12 | CMS-1500 (with home infusion) | Generally not used for IV cytotoxic chemo with vesicant risk |
Claim form field mapping Verified May 2026
| Information | CMS-1500 box | Notes |
|---|---|---|
| NPI | 17b | Rendering provider |
| NDC qualifier + 11-digit NDC + UoM + qty | 24A shaded area | N4 + product NDC + ML + total volume drawn |
| HCPCS Q2050 + JZ (admin line) | 24D | Units administered |
| HCPCS Q2050 + JW (waste line) | 24D (separate line) | Discarded units |
| Drug units administered | 24G | 10 mg per unit; round per MAC policy |
| CPT 96413 (admin line) | 24D | Add 96415 / 96417 if extended chair time or combo |
| ICD-10 | 21 | C56.x (ovarian), C46.x (KS), C90.0x (MM); pair B20 with C46.x for AIDS-KS |
| PA number | 23 | Required by all major payers |
Phase 3
Get paid
PA + indication-specific criteria + LVEF baseline. Generic Lipodox is typically preferred for cost.
Payer policy snapshot Reviewed May 2026
| Payer | PA? | Key criteria | Generic preference |
|---|---|---|---|
| UnitedHealthcare Oncology Med Coverage Policy |
Yes | Indication-specific (post-platinum for ovarian; AIDS-KS post-prior failure; MM + bortezomib post-≥1 prior); LVEF baseline; cumulative dose tracking | Generic Lipodox typically preferred for cost |
| Aetna CPB + Medical Drug policies |
Yes | NCCN-aligned indication criteria; LVEF baseline; HFS management documented for continued therapy | Generic typically preferred |
| BCBS plans Vary by plan |
Yes | Generally aligned with NCCN guidelines + FDA label indication restrictions | Plan-specific |
Step therapy
Generally no step therapy through other agents — Doxil's three indications all already require failure of prior therapy as part of the FDA label (post-platinum, post-prior failure, post-≥1 prior therapy). PA criteria typically restate the FDA-label prior-therapy requirement.
Medicare reimbursement CMS Q2 2026 (live)
Quarterly ASP from CMS Part B Drug Pricing File. Refreshes automatically each quarter.
Q2 2026 payment snapshot — Q2050
Effective April 1 – June 30, 2026 · Based on 4Q25 ASP submissions
ASP + 6%
$71.861
per 10 mg unit
85 mg dose (1.7 m² ovarian)
$646.75
9 units × ASP+6%
vs J9000 conventional
$2.729
per 10 mg unit (~26× cheaper)
Annualized cost (ovarian regimen, 50 mg/m² q4wk): 13 cycles/year ×
~$646.75/cycle (drug only, BSA 1.7 m²) = ~$8,408/year before waste line and
sequestration. Add 10–25% for typical waste-line billing under JW.
Coverage
No NCD specific to liposomal doxorubicin. Coverage falls under MAC LCDs for biologics and the generic drug-coverage framework. All MACs cover Q2050 for FDA-approved on-label indications with appropriate ICD-10 documentation and LVEF baseline.
Patient assistance — Janssen CarePath / Doxil Patient Support Verified May 2026
- Janssen CarePath / Doxil Patient Support: 1-877-CarePath (1-877-227-3728) — benefits investigation, prior authorization assistance, appeal support, copay assistance enrollment
- Janssen Commercial Copay Program: commercial copay support; eligible commercially-insured patients (excludes Medicare, Medicaid, federal program patients)
- Johnson & Johnson Patient Assistance Foundation: free product for uninsured / underinsured patients meeting income requirements
- Sun Pharma Lipodox support: verify current Sun Pharma patient support program for the generic
- Foundations: for Medicare patients, refer to PAN, HealthWell, CancerCare — verify open ovarian / multiple myeloma / Kaposi sarcoma funds quarterly
Need to model what a specific patient will actually pay after copay assistance, deductible, coinsurance,
and OOP max? Run a CareCost Estimate — Q2050 pre-loaded.
Phase 4
Safety — boxed warnings & cumulative-dose stewardship
Cardiotoxicity, hand-foot syndrome, and 550 mg/m² lifetime cap require active tracking.
Cardiotoxicity warning FDA boxed warning
BOXED WARNING — Cardiomyopathy / heart failure. The risk of cardiomyopathy
increases with cumulative doxorubicin dose. Pegylated liposomal pharmacokinetics reduce acute peak
cardiac exposure compared to conventional doxorubicin, but cumulative-dose cardiotoxicity remains real
and is the dose-limiting late toxicity. Obtain baseline LVEF (echo or MUGA) before initiation and
repeat per institutional protocol — particularly as cumulative dose approaches the cap.
Baseline LVEF assessment is a payer-required PA element for many UHC, Aetna, and BCBS oncology policies. Document the baseline LVEF in the chart and the date obtained, and re-assess on the schedule defined by your institution's anthracycline cardiotoxicity protocol. Cardio-oncology consult is appropriate for patients with baseline LVEF <55%, prior anthracycline exposure, or other cardiac risk factors.
Cumulative dose tracking — 550 mg/m² lifetime cap FDA label
Lifetime cumulative cap: 550 mg/m² doxorubicin equivalents. Pegylated liposomal
doxorubicin's cumulative dose counts toward the patient's lifetime anthracycline exposure together
with any prior conventional doxorubicin (J9000), daunorubicin, idarubicin, or mitoxantrone (converted
to doxorubicin equivalents per institutional protocol). The cap is a lifetime total, not a per-regimen
total. Track in the chart from Cycle 1.
Tracking workflow
- At Cycle 1: capture prior anthracycline exposure (drug, dose, total) from prior treatment records.
- Convert prior exposures to doxorubicin equivalents per institutional cardiotoxicity protocol.
- Add cumulative Doxil mg/m² after each cycle; record running total in the chart.
- Trigger cardio-oncology consult and consider holding therapy as cumulative exposure approaches 450 mg/m².
- At 550 mg/m²: do not exceed without explicit informed-consent and documented benefit/risk discussion.
Pre-mortem: A patient who received 4 cycles of conventional doxorubicin AC for early
breast cancer years ago (60 mg/m² × 4 = 240 mg/m²) and now needs Doxil for recurrent
ovarian cancer is starting at 240 mg/m² cumulative — only 310 mg/m² of headroom remains.
Plan accordingly; do not prescribe blind to prior exposure.
Hand-foot syndrome (palmar-plantar erythrodysesthesia) Doxil-specific
HFS is the Doxil-specific hallmark toxicity. Approximately 50% incidence with Doxil
/ Lipodox vs <5% with conventional doxorubicin (J9000). Cumulative and dose-limiting. Caused by
liposome accumulation in palm/sole capillaries with local doxorubicin release.
Prevention
- Cool extremities during infusion (cooling gloves and socks; ice packs to palms/soles).
- Avoid pressure and friction to palms/soles for 4–7 days post-infusion (no jogging, no constrictive footwear, no heavy gripping).
- Avoid heat exposure (hot showers, hot tubs, prolonged sun) for 4–7 days post-infusion.
- Counsel patients on early symptom recognition: tingling, redness, mild swelling on palms/soles.
Management by grade
- Grade 1 (mild erythema, swelling, no pain): supportive care; continue current dose.
- Grade 2 (painful erythema with swelling, interference with ADLs): delay next cycle; reduce dose 25% on resumption.
- Grade 3 (moist desquamation, ulceration, blistering, severe pain): hold therapy; resume at reduced dose only after recovery to Grade ≤1.
- Grade 4: discontinue.
Document HFS grade and dose modifications in the chart. Payers may require evidence of
grade-appropriate management before approving continued therapy at the original dose. A claim for
full-dose Cycle 4 after a documented Grade 3 HFS event in Cycle 3 will be questioned.
Phase 5
Fix problems
Q2050/J9000 confusion, missing JW, and indication-criteria gaps are the top three.
Common denials & how to fix them
| Denial reason | Common cause | Fix |
|---|---|---|
| Wrong HCPCS code (J9000 billed for Doxil) | Confusion between liposomal Q2050 and conventional J9000 | Resubmit as Q2050. The two are different drugs — always match the formulation administered. |
| JW missing on BSA-based dose | Wasted drug not reported on Q2050 claim | Add JW line for discarded units. JZ on administered, JW on wasted — both must reconcile to total vials drawn. |
| JZ missing | Single-dose vial claim without JZ on the admin line | Resubmit with JZ. One of JZ or JW must appear on every Q2050 claim (CMS 7/1/2023 policy). |
| Indication-specific PA criteria not met | ICD-10 alone insufficient; prior-therapy history not documented | Submit complete prior-therapy history (post-platinum for ovarian, post-prior failure for AIDS-KS, post-≥1 prior therapy for MM). |
| Missing LVEF baseline | Cardiac assessment not documented before initiation | Submit baseline LVEF (echo or MUGA) result; payer requires baseline + monitoring per anthracycline policy. |
| Cumulative dose exceeded without documentation | Patient at or near 550 mg/m² cumulative without informed-consent + benefit/risk note | Submit cumulative dose tracking, current LVEF, and documented benefit/risk discussion. |
| Continued full dose after Grade 3 HFS | Dose modification not documented after prior cycle's HFS event | Submit chart note showing HFS recovery to Grade ≤1 and rationale for current dose. |
| Wrong admin code (96365) | Therapeutic IV billed instead of chemo IV | Resubmit with 96413. Doxil is a cytotoxic chemo and bills under chemo admin. |
| Site of care (HOPD) | HOPD administration after first 1–3 cycles on commercial plan with site-of-care UM | Move to office (POS 11) or AIC (POS 49). Submit medical necessity letter if HOPD required. |
| Generic preferred (originator denied) | Doxil billed when payer prefers generic Lipodox | Switch to generic Lipodox or submit medical necessity for branded Doxil. |
Frequently asked questions
What is the HCPCS code for Doxil / Lipodox?
Doxil and Lipodox (pegylated liposomal doxorubicin HCl) bill under HCPCS Q2050 —
"Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg." One unit equals
10 mg (NOT 1 mg). Q2050 is distinct from J9000 (conventional non-liposomal doxorubicin), which is
also a 10 mg unit but represents a completely different drug with a different ASP, different toxicity
profile, and different label.
Is Doxil the same as conventional doxorubicin (J9000)?
No. Doxil / Lipodox (Q2050) is pegylated LIPOSOMAL doxorubicin — the active ingredient is encapsulated in long-circulating PEG-coated liposomes. Conventional doxorubicin HCl (J9000) is the non-liposomal free-drug form. Different pharmacokinetics, different toxicity profile, different labeled indications, different ASP (~26× more expensive). See the formulation comparison.
How many units do I bill for a 50 mg/m² Doxil dose?
For a typical 1.7 m² ovarian patient receiving 50 mg/m²: 50 × 1.7 = 85 mg actual dose. With 10-mg-per-unit billing under Q2050, that is 8.5 units — you cannot bill fractional units, and you cannot make 85 mg from whole vials (20 + 50 = 70 mg, or 50 + 50 = 100 mg). Use two 50 mg vials (100 mg), administer 85 mg, and bill 9 units administered with JZ + 2 units waste with JW (rounding per MAC policy).
Do I bill JZ or JW for Doxil?
Both apply — frequently together. BSA-based dosing with fixed 20 mg and 50 mg vials almost never lands on whole-vial multiples. Bill JZ on the units administered line and JW on the wasted units line. One of JZ or JW must appear on every Q2050 claim per CMS's July 2023 single-dose container policy.
What administration CPT do I use for Doxil?
CPT 96413 — "Chemotherapy administration, IV infusion technique; up to 1 hour, single
or initial substance/drug." Doxil is administered IV over approximately 60 minutes (start at 1 mg/min
for the first dose to monitor for infusion reactions, then titrate up). 96413 covers the first hour;
add 96415 if chair time exceeds 1 hour, or 96417 for sequential infusions same-day in the MM regimen.
What is the Medicare reimbursement for Q2050?
For Q2 2026, the Medicare Part B payment limit for Q2050 is $71.861 per 10 mg unit (ASP + 6%). For a typical 85 mg ovarian dose: 9 units = ~$646.75 per dose. For a 30 mg/m² myeloma dose at 1.7 m² = 51 mg: ~6 units = $431.17 per cycle. Conventional doxorubicin J9000 by comparison is $2.729 per 10 mg unit — Doxil is approximately 26× more expensive per mg.
What is the lifetime cumulative dose limit for Doxil?
550 mg/m² lifetime cumulative doxorubicin (counting both Doxil and any prior conventional doxorubicin / daunorubicin / idarubicin / mitoxantrone exposure converted to doxorubicin equivalents). Driven by cumulative-dose cardiotoxicity. Baseline LVEF assessment plus periodic monitoring required; obtain MUGA or echo per institutional protocol before each cycle approaching cap. See cumulative dose tracking.
What is hand-foot syndrome and why does Doxil cause it?
Palmar-plantar erythrodysesthesia (PPE / HFS) is a cutaneous toxicity unique to liposomal-doxorubicin pharmacokinetics. The liposomes accumulate in capillaries of the palms and soles, releasing doxorubicin into the skin and causing painful erythema, blistering, and desquamation. Incidence is approximately 50% with Doxil (vs <5% with conventional doxorubicin J9000). Cumulative and dose-limiting. See hand-foot syndrome.
Reference
Sources & methodology
Every claim on this page is sourced. Methodology and review history below.
Source documents
- DailyMed — DOXIL (doxorubicin hydrochloride liposomal) Prescribing Information
- DailyMed — LIPODOX (doxorubicin hydrochloride liposomal) Prescribing Information
- FDA Drugs@FDA — Doxil approval history (NDA 050718)
- CMS — Medicare Part B Drug ASP Pricing File
- SEER CanMED — HCPCS Q2050 reference
- NCCN Clinical Practice Guidelines
- Janssen CarePath — Doxil Patient Support
- UnitedHealthcare — Oncology Medication Clinical Coverage Policy
- Aetna — Clinical Policy Bulletins (oncology medical drugs)
- FDA National Drug Code Directory
About this page
We maintain this page as a living reference. Medicare ASP pricing is bound to our underlying CareCost data layer and refreshes automatically when CMS publishes new quarterly files. Coding and policy content is reviewed at least quarterly and updated whenever a source document changes.
Found an error? Email hello@carecostestimate.com.
Refresh cadence
| Element | Cadence | How it's refreshed |
|---|---|---|
| Medicare ASP pricing | Quarterly | Auto-bound to CareCost ASP layer; updates on CMS file release. |
| Payer policies (UHC, Aetna, BCBS) | Semi-annual | Manual review against published payer policy documents. |
| HCPCS / CPT / modifier rules | Annual | Reviewed against CMS HCPCS quarterly files and AMA CPT releases. |
| NDC, dosing, FDA label, indication list, boxed warnings | Event-driven | Tied to FDA label revision and manufacturer document version. |
Reviewer
Pending SME review. This page is staff-authored from primary sources (FDA label,
CMS ASP file, manufacturer materials, payer policy documents — all linked above). Final review
by the CareCost editorial team, the CareCost editorial team, is in progress. Until that review is complete, treat this as a draft
reference and verify each cited source for high-stakes claims.
Change log
- — Initial publication. ASP data: Q2 2026. FDA label: current. Manufacturer source: Janssen CarePath. 4 boxed warnings + 550 mg/m² lifetime cap + ~50% HFS incidence highlighted vs conventional doxorubicin J9000.
Methodology
Every claim on this page is sourced inline. Pricing reflects the current CMS Part B Drug ASP Pricing File. Payer policies are read directly from each payer's published medical/pharmacy policy documents. Indication list is verified against the current FDA label revision. We do not paraphrase from billing-software vendor blogs.